IOVANCE BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $0.00 per share for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2019-02-28
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2017-03-31 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2016-03-31 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2016 was $7.02, a 3.08% increase from fiscal 2015.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2015 was $6.81.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2014 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-03-12 | |||
| 2017-09-30 | $0.00 10-Q · filed 2017-11-02 | |||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-03 | |||
| 2016-12-31 | $7.02 10-K · filed 2019-02-28 | |||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-04 | |||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | $6.81 10-K · filed 2018-03-12 | |||
| 2015-09-30 | $8.24 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | $8.55 10-Q · filed 2015-08-10 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |